Brain tumor

Y-mAbs Announces Update on Omburtamab for DIPG

Retrieved on: 
Friday, June 4, 2021
Chemical elements, Pediatric cancers, Chemistry, Physical sciences, Brain tumor, Chlorides, Radiopharmaceuticals, Medulloblastoma, Lutetium, Neuroblastoma, Blastoma

We are excited to share these results that significantly broaden the potential reach of omburtamab, which would be addressing a clear unmet medical need.

Key Points: 
  • We are excited to share these results that significantly broaden the potential reach of omburtamab, which would be addressing a clear unmet medical need.
  • The results pave the way for our multicenter phase 2 study in DIPG later this year, where we expect to give up to three repeated doses of omburtamab, stated Thomas Gad, founder, Chairman and President.
  • Dr. Claus Moller, Chief Executive Officer, continued, We are expanding our omburtamab franchise significantly this year.
  • While the iodine labeled omburtamab targets DIPG, CNS/LM from neuroblastoma and DSRCT, we have also initiated clinical trials for medulloblastoma and B7-H3 positive CNS metastasis with our lutetium labeled omburtamab.

Worldwide Brain Tumor Community Comes Together in EBCI's Virtual Patient Education Meeting & Event

Retrieved on: 
Thursday, June 3, 2021
Brain tumor

SEATTLE, June 3, 2021 /PRNewswire/ --The EndBrainCancer Initiative(EBCI) recently hosted the first of a virtual "Know Your Treatment Options" Patient Education Meeting and Event series on Wednesday, May 26th to a worldwide audience of brain cancer patients, survivors, caregivers, and families.

Key Points: 
  • SEATTLE, June 3, 2021 /PRNewswire/ --The EndBrainCancer Initiative(EBCI) recently hosted the first of a virtual "Know Your Treatment Options" Patient Education Meeting and Event series on Wednesday, May 26th to a worldwide audience of brain cancer patients, survivors, caregivers, and families.
  • The educational meeting started with three 2021 National HOPE Award Finalists stories of courage and inspiration presented by EBCI Executive Director, Susan Kellner.
  • According to the EndBrainCancer Initiative, Dr. Rinker holds a very special place in the hearts and minds of the brain tumor community having used this time to continue his mission of teaching and creating optimism in the world.
  • The current clinical trial landscape for patients with brain tumor patients.

Kintara Therapeutics to Present at the LD Micro Virtual Invitational Conference on June 9, 2021

Retrieved on: 
Wednesday, June 2, 2021
Life sciences, Health sciences, Biotechnology, Brain tumor, Specialty drugs, Breast cancer, Metastatic breast cancer, Glioblastoma, GBM, Biopharmaceutical

(Nasdaq: KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announced today that Chief Executive Officer Saiid Zarrabian will present a corporate overview at the three-day LD Micro Virtual Invitational Conference being held on June 8 10, 2021.

Key Points: 
  • (Nasdaq: KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announced today that Chief Executive Officer Saiid Zarrabian will present a corporate overview at the three-day LD Micro Virtual Invitational Conference being held on June 8 10, 2021.
  • Mr. Zarrabian will deliver his corporate presentation on June 9 at 2:30 pm ET, Track 1.
  • Located in San Diego, California, Kintara (Nasdaq: KTRA) is dedicated to the development of novel cancer therapies for patients with rare unmet medical needs.
  • Kintara is currently developing two Phase 3-ready therapeutics, VAL-083 for glioblastoma multiforme (GBM) and REM-001 for cutaneous metastatic breast cancer (CMBC).

Prelude Therapeutics Announces Participation at Two Upcoming Virtual Investor Conferences

Retrieved on: 
Wednesday, June 2, 2021
Cancer, Brain tumor, Clinical medicine, Medicine, Glioblastoma, Oncology

WILMINGTON, Del., June 02, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that members of its management team will participate in two upcoming virtual investor conferences:

Key Points: 
  • WILMINGTON, Del., June 02, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that members of its management team will participate in two upcoming virtual investor conferences:
    Fireside chat at 8:00 a.m.
  • Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways.
  • Preludes first clinical candidate, PRT543, is in Phase 1 development for advanced solid tumors and select myeloid malignancies.
  • Prelude is also advancing PRT811, a second PRMT5 inhibitor optimized for high brain exposure, in a Phase 1 clinical trial including glioblastoma multiforme (GBM).

NOXXON Announces Positive Results From Second Cohort in Phase 1/2 NOX-A12 Brain Cancer Trial

Retrieved on: 
Tuesday, June 8, 2021
Biotechnology, Health, Pharmaceutical, Optical, Clinical trials, Cancer, Health, Medicine, Oncology, Noxxon Pharma, Brain tumor, Glioblastoma, Treatment of cancer, Blastoma, Biotechnology, Health, Pharmaceutical, Optical, Clinical trials, Cancer, Health, Clinical medicine, Oncology, Noxxon Pharma, Brain tumor, Glioblastoma, Treatment of cancer, Blastoma

NOXXON Pharma N.V. (Paris:ALNOX) (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today positive results from the second cohort in its Phase 1/2 study of NOX-A12 in combination with radiotherapy in patients with brain cancer (Glioblastoma Multiforme).

Key Points: 
  • NOXXON Pharma N.V. (Paris:ALNOX) (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today positive results from the second cohort in its Phase 1/2 study of NOX-A12 in combination with radiotherapy in patients with brain cancer (Glioblastoma Multiforme).
  • The study investigates three dose regimens of NOX-A12 (200, 400 and 600 mg/week), each combined with external-beam radiotherapy in newly diagnosed brain cancer patients.
  • In three of the six patients, smaller satellite lesions that were present before therapy around the primary tumor completely disappeared.
  • Enrolment of patients in the third cohort has been completed and we expect results from the last cohort in Q4 2021, commented Aram Mangasarian, CEO of NOXXON.

Global Glioblastoma Multiforme Treatment Markets, 2015-2020 & 2021-2026 - Industry Trends, Share, Size, Growth, Opportunity and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Monday, May 31, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Cancer, Brain tumor, Health, Branches of biology, Glioblastoma, Oncology, Glioblast, Blastoma

The "Glioblastoma Multiforme Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Glioblastoma Multiforme Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • Looking forward, the global glioblastoma multiforme treatment market to grow at a CAGR of around 9% during 2021-2026.
  • What is the structure of the global glioblastoma multiforme treatment industry and who are the key players?
  • What is the degree of competition in the global glioblastoma multiforme treatment industry?

Global Glioblastoma Multiforme (GBM) Market to 2030 - Insights, Epidemiology and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Monday, May 31, 2021
Health, Biotechnology, Cancer, Brain tumor, Health, Glioblastoma, Oncology, Causes of death, GBM, Glioblast, Blastoma

The "Glioblastoma Multiforme (GBM) - Market Insights, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Glioblastoma Multiforme (GBM) - Market Insights, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
  • This report delivers an in-depth understanding of the Glioblastoma Multiforme (GBM), historical and forecasted epidemiology as well as the Glioblastoma Multiforme (GBM) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
  • The Glioblastoma Multiforme (GBM) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Glioblastoma Multiforme (GBM) market size from 2017 to 2030.
  • This section provides the total Glioblastoma Multiforme (GBM) market size and market size by therapies in the United States.

NhTherAguix: NH TherAguix and the CHU Grenoble-Alpes announce the publication of the results of the First-In-Human phase 1 clinical trial on the combination of AGuIX with radiotherapy

Retrieved on: 
Monday, May 31, 2021
Medicine, Clinical medicine, Medical physics, Radiobiology, Brain tumor, Radiation therapy, Radioactivity, Brain metastasis, Prophylactic cranial irradiation, Limited-stage small cell lung carcinoma

NH TherAguix and the CHU Grenoble-Alpes announce the publication of the results of the First-In-Human phase 1 clinical trial on the combination of AGuIX with radiotherapy on multiple brain metastases patients.

Key Points: 
  • NH TherAguix and the CHU Grenoble-Alpes announce the publication of the results of the First-In-Human phase 1 clinical trial on the combination of AGuIX with radiotherapy on multiple brain metastases patients.
  • All patients have received one intravenous injection of AGuIX associated with a conventional whole brain radiation therapy (10 x 3 Gy).
  • This trial has demonstrated that the combination of AGuIX with radiotherapy for these patients is safe and feasible.
  • Thus, the dose of 100 mg/kg, reached without occurrence of dose limiting toxicities, was selected for the phase II trial that is currently ongoing.

The 4th Annual Art of Surviving Showcases the Creativity of the Global Brain Tumor Community During Brain Tumor Awareness Month

Retrieved on: 
Thursday, May 27, 2021
Anatomy, Neuroendocrinology, Branches of biology, Brain tumor, Pituitary gland

Wood Foundation helps improve the quality of life for hypothalamic-pituitary brain tumor survivors by providing access to education, technology, and evolving treatments.

Key Points: 
  • Wood Foundation helps improve the quality of life for hypothalamic-pituitary brain tumor survivors by providing access to education, technology, and evolving treatments.
  • Many brain tumor survivors use art as a way to cope with the challenges that come with treatment, a means to calm and focus a healing brainor an opportunity to express their experiences.
  • "He had never really been interested in art prior to his tumor treatment, and then suddenly coloring and drawing were his go-to," said Wood.
  • "I thought providing a platform for sharing artwork would be a positive thing for the foundation to do during Brain Tumor Awareness Month,"said Wood.

Novocure Announces Clinical Trial Collaboration with GT Medical Technologies to Evaluate Tumor Treating Fields Together with GammaTile® Therapy in Recurrent Glioblastoma

Retrieved on: 
Tuesday, May 25, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical trials, Health sciences, Medicine, Clinical medicine, Cancer treatments, Medical physics, Brain tumor, Alternating electric field therapy, Glioblastoma, Radiation therapy, Therapy, Tumor Treating Fields, Novocure, GammaTile Therapy, GT Medical Technologies, Inc., TUMOR TREATING FIELDS, NOVOCURE, GAMMATILE THERAPY, GT MEDICAL TECHNOLOGIES, INC.

Novocure (NASDAQ: NVCR) today announced it has entered into a clinical trial collaboration agreement with GT Medical Technologies, Inc., to develop Tumor Treating Fields (TTFields) together with GT Medical Technologies GammaTile Surgically Targeted Radiation Therapy (STaRT) for treatment of recurrent glioblastoma (GBM).

Key Points: 
  • Novocure (NASDAQ: NVCR) today announced it has entered into a clinical trial collaboration agreement with GT Medical Technologies, Inc., to develop Tumor Treating Fields (TTFields) together with GT Medical Technologies GammaTile Surgically Targeted Radiation Therapy (STaRT) for treatment of recurrent glioblastoma (GBM).
  • Novocure and GT Medical Technologies plan to conduct a phase 2 pilot study to test the effectiveness and safety of neo-adjuvant TTFields followed by resection, GammaTile Therapy, and adjuvant TTFields for recurrent GBM.
  • GT Medical Technologies is enthusiastic about the potential of these combined therapies, said Matthew E. Likens, President and CEO of GT Medical Technologies.
  • Tumor Treating Fields, or TTFields, are electric fields that disrupt cancer cell division.